Heron Therapeutics' Zynrelef Gets FDA Approval For Managing Post-Operative Pain For 72 Hours

Heron Therapeutics, Inc. (HRTX), Thursday announced the FDA approval for Zynrelef in Managing postoperative pain for up to 72 hours. The company noted that the extended-release dual-acting local anesthetic could eliminate the need for opioids in pain management for up to 72 hours compared to the standard of care bupivacaine solution.

Zynrelef is intended to use in adults undergoing soft tissue or periarticular instillation to produce postsurgical analgesia after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty.

Heron plans a commercial launch in July 2021.

The drug during the phase 3 studies have demonstrated superiority to bupivacaine solution. Clinical studies included over 1,000 patients.

In U.S. 67 percent of patients undergoing surgeries were managed through opioids

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Google has revoked its three-year ban on cryptocurrency-related ads on its sites under the search giants' new ad services policy. This action will now allow cryptocurrency exchanges and wallets certified by Google to advertise their products and services on Google's network, beginning August 3, 2021. The UK's competition regulator said Friday that it has secured commitments from Google to address concerns about the tech giant's proposal to remove third-party cookies from Chrome browser. Archer Aviation, a developer of electric vertical take-off and landing or eVTOL aircraft, unveiled its autonomous electric two-seater aircraft, named "Maker", marking a milestone towards its commercial launch. The California-based air mobility company, which has already received orders from United Airlines, will use its inaugural aircraft prototype for testing as it works towards certification.
Follow RTT